BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Moleculin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Moleculin's drugs run\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06788756-10896@assetmemo.bio
DTSTAMP:20261121T005828Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Annamycin: Phase 2/3 readout est. (NCT06788756)
DESCRIPTION:Annamycin\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: L-Annam
 ycin for Injection in Combination With Cytarabine Injection as Second Line
  Therapy for Remission Induction in Adult Subjects With Refractory/Relapse
 d AML\nEstimated primary completion: August 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/annamycin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06788756
URL:https://assetmemo.bio/drug/annamycin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
